Current Trends in Organ Preservation Solutions for Pancreas Transplantation: A Single-Center Retrospective Study

• Published in: Transplant international 2022-03, Vol.35, p.10419-10419
• Main Authors: Ferrer-Fàbrega, Joana, Folch-Puy, Emma, Lozano, Juan José, Ventura-Aguiar, Pedro, Cárdenas, Gabriel, Paredes, David, García-Criado, Ángeles, Bombí, Josep Antoni, García-Pérez, Rocío, López-Boado, Miguel Ángel, Rull, Ramón, Esmatjes, Enric, Ricart, Maria José, Diekmann, Fritz, Fondevila, Constantino, Fernández-Cruz, Laureano, Fuster, Josep, García-Valdecasas, Juan Carlos
• Format: Article
• Language: English
• Subjects: Glucose; Health Archive; Humans; Insulin - therapeutic use; Organ Preservation; Organ Preservation Solutions; Pancreas; Pancreas Transplantation; Retrospective Studies
• ISSN: 1432-2277; 0934-0874; 1432-2277
• DOI: 10.3389/ti.2022.10419

Due to the high vulnerability of the pancreas to ischemia-reperfusion injury, choices regarding preservation solution markedly affect pancreas transplant success. A retrospective single-center analysis of 380 pancreas transplants (2000-2019) was performed to correlate current preservation solutions with transplant outcomes. Early graft failure requiring transplantectomy within 30 days post-transplant occurred in 7.5% for University of Wisconsin (UW) group ( = 267), 10.8% of Celsior (CS) group ( = 83), 28.5% of Histidine-Tryptophan-Ketoglutarate (HTK) group ( = 7), and none for Institut Georges Lopez-1 (IGL-1) group ( = 23). The most common causes of technical failures in this cohort included abdominal hemorrhage (8.4%); graft pancreatitis (3.7%); fluid collections (2.6%); intestinal complications (6.6%); and vascular thrombosis (20.5%). Although IGL-1 solution provided lower surgical complication rates, no significant differences were found between studied groups. Nevertheless, HTK solution was associated with elevated pancreatitis rates. The best graft survival was achieved at 1 year using UW and IGL-1, and at 3 and 5 years using IGL-1 ( = 0.017). There were no significant differences in patient survival after a median follow-up of 118.4 months. In this setting therefore, IGL-1 solution appears promising for perfusion and organ preservation in clinical pancreas transplantation, compared to other commonly used solutions.